Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
This is a phase 4 study to evaluate with Polysomnography (PSG) and subjective measures the
 effect of Rotigotine on sleep efficiency, maintenance, insomnia, nocturnal akinesia and
 night-time movement in bed, in patients with advanced Parkinson's disease.
Inclusion Criteria:

 -  Advanced Parkinson's disease (ie, takes Levodopa (L-DOPA))

 -  Hoehn and Yahr stage score of 2 to 4

 -  Subject has sleep-maintenance insomnia

 Exclusion Criteria:

 -  Significant skin disease that would make transdermal drug use inappropriate

 -  Subject received therapy with controlled-release Levodopa (L-DOPA), entacapone or
 Stalevo® within 28 days prior to the Baseline Visit or has received therapy with
 Tolcapone

 -  Atypical Parkinsonian syndromes

 -  Previous diagnosis of Narcolepsy, Sleep Apnoea Syndrome, significant Rapid Eye
 Movement (REM) Sleep Behavior Disorder (RBD), moderate to severe Restless Legs
 Syndrome (RLS) or Periodic Limb Movement Disorder